Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | FAP | Q12884 | 5/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31512419 | 0.84 | NSD2 (0.67) | MEN1KMT2ANSD2EGLN1 | |
| SCHEMBL5577362 | 0.83 | MEN1 (0.58) | MEN1KMT2ADRD4CHRM4CXCR3 | |
| SCHEMBL5577706 | 0.80 | PROKR1 (0.52) | CCR3MEN1KMT2ACHRM4EGLN1 | |
| SCHEMBL5577771 | 0.80 | DRD2 (0.53) | CCR3DRD4NSD2 | |
| SCHEMBL5577369 | 0.79 | MAPT (0.57) | MEN1KMT2ACHRM4EGLN1 | |
| SCHEMBL10291897 | 0.74 | CCR1 (0.69) | — | |
| SCHEMBL2159728 | 0.74 | CCR1 (0.69) | — | |
| SCHEMBL10291900 | 0.73 | CCR1 (0.70) | — | |
| SCHEMBL12396998 | 0.73 | CCR1 (0.70) | — | |
| SCHEMBL5577650 | 0.72 | MEN1 (0.62) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CCR3 120/4885MEN1 748/4885KMT2A 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.